Advertisement
UK markets close in 6 hours 35 minutes
  • FTSE 100

    8,083.56
    +38.75 (+0.48%)
     
  • FTSE 250

    19,797.36
    -2.36 (-0.01%)
     
  • AIM

    755.62
    +0.75 (+0.10%)
     
  • GBP/EUR

    1.1629
    +0.0001 (+0.01%)
     
  • GBP/USD

    1.2425
    -0.0028 (-0.22%)
     
  • Bitcoin GBP

    53,545.98
    +294.39 (+0.55%)
     
  • CMC Crypto 200

    1,435.83
    +11.73 (+0.82%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CRUDE OIL

    82.98
    -0.38 (-0.46%)
     
  • GOLD FUTURES

    2,329.70
    -12.40 (-0.53%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • DAX

    18,209.25
    +71.60 (+0.39%)
     
  • CAC 40

    8,122.82
    +17.04 (+0.21%)
     

Nitric Oxide Markets, Therapeutics, and Competitive Landscape Report 2021 with Profiles of 36 Companies

Dublin, Nov. 18, 2021 (GLOBE NEWSWIRE) -- The "Nitric Oxide - Therapeutics, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

This report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based drugs are described as well as the companies involved in developing them.

Nitric oxide (NO) can generate free radicals as well as scavenge them. It also functions as a signaling molecule and has an important role in the pathogenesis of several diseases. A major focus is delivery of NO by various technologies. Another approach is modulation of nitric oxide synthase (NOS), which converts L-arginine to NO. NOS can be stimulated as well as inhibited by pharmacological and gene therapy approaches.

Important therapeutic areas for NO-based therapies are inflammatory disorders, cardiovascular diseases, erectile dysfunction, inflammation, pain and neuroprotection. The first therapeutic use of NO was by inhalation for acute respiratory distress syndrome (ARDS). NO-donors, NO-mimics and NOS modulators are described and compared along with developmental status. NO-related mechanisms of action in existing drugs are identified.

Various pharmacological approaches are described along with their therapeutic relevance. Various approaches are compared using SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis. NO-based therapies are compared with conventional approaches and opportunities for combination with modern biotechnology approaches are described.

Share of drugs where NO is involved in the mechanism of action is analyzed in the worldwide pharmaceutical market for 2020 and is projected to 2024 and 2030 as new drugs with NO-based mechanisms are introduced into the market. Various strategies for developing such drugs are discussed.

Several companies have a product or products involving NO and free radicals. The report includes profiles of 36 companies involved in this area of which 10 have a significant interest in NO-based therapeutics. Other players are pharmaceutical and biotechnology companies as well as suppliers of products for NO research. Unfulfilled needs in the development of NO-based therapeutics are identified. Important 18 collaborations in this area are tabulated.

There are numerous publications relevant to NO. Selected 500 references are included in the bibliography. The text is supplemented with 26 tables and 30 figures. It is concluded that the future prospects for NO-based therapies are bright and fit in with biotechnology-based approaches to modern drug discovery and development. It is anticipated that some of these products will help in meeting the unfulfilled needs in human therapeutics.

Markets for NO-based Therapies

  • Introduction

  • Impact of NO-based therapies on international markets

  • Share of NO-based therapies in major therapeutic areas

  • Share of NO-based therapies in cardiovascular disorders

  • Hypercholesterolemia

  • Myocardial infarction

  • Angina pectoris/coronary artery disease

  • Heart failure

  • Coronary restenosis and stenting

  • Strategies for developing NO-based therapy markets

  • Addressing the unfulfilled needs

  • Multidisciplinary approaches

  • Collaboration between the academia and the industry

  • Education of the public

ADVERTISEMENT

Competitive Landscape

  • Profiles of companies with focus on NO

  • Major pharmaceutical companies with involvement in NO

  • Smaller biotech and pharmaceutical companies involved in NO

  • Biopharmaceutical companies involved in antioxidant research

  • Companies supplying NO equipment for healthcare

  • Academic institutes with commercial collaboration in NO research

  • Companies supplying NO products for research

  • Collaborations

Key Topics Covered:

Executive Summary

1. Introduction

2. Nitric Oxide Pathways

3. Role of NO in Physiology

4. Role of NO in Diseases

5. Pharmacology of Nitric Oxide

6. Therapeutic Applications

7. Evaluation of NO-Based Drugs

8. Markets for NO-based Therapies

9. Companies

For more information about this report visit https://www.researchandmarkets.com/r/wttflp


CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900